| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PNAS..10620228S |
| P356 | DOI | 10.1073/PNAS.0910757106 |
| P8608 | Fatcat ID | release_5pra5goixbc4ljh22la7jtd3oq |
| P932 | PMC publication ID | 2787169 |
| P698 | PubMed publication ID | 19906985 |
| P5875 | ResearchGate publication ID | 38083502 |
| P2093 | author name string | Li Yang | |
| Hui Zheng | |||
| Hakim Djaballah | |||
| Rong Wang | |||
| Lei Zhu | |||
| Yue-Ming Li | |||
| Christopher C Shelton | |||
| Deming Chau | |||
| P2860 | cites work | Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state | Q22254058 |
| Gleevec inhibits β-amyloid production but not Notch cleavage | Q24683037 | ||
| On the size of the active site in proteases. I. Papain | Q27860826 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 | Q28139001 | ||
| Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans | Q28145545 | ||
| Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide | Q28201180 | ||
| Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production | Q28245521 | ||
| Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain | Q28273268 | ||
| Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms | Q28290934 | ||
| Spatial segregation of gamma-secretase and substrates in distinct membrane domains | Q28591973 | ||
| Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells | Q29614268 | ||
| Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity | Q29616491 | ||
| Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. | Q33245678 | ||
| Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution | Q33694348 | ||
| Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo | Q34063772 | ||
| A common enzyme connects notch signaling and Alzheimer's disease | Q34088470 | ||
| {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. | Q34635580 | ||
| Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex | Q35105866 | ||
| gamma-Secretase as a target for drug intervention in Alzheimer's disease. | Q35927325 | ||
| The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry | Q36835366 | ||
| Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes | Q37075276 | ||
| Substrate-targeting gamma-secretase modulators | Q37182828 | ||
| Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct | Q37705090 | ||
| Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. | Q40052618 | ||
| Stereo-controlled synthesis of novel photoreactive gamma-secretase inhibitors | Q40278030 | ||
| Mutations in APP have independent effects on Abeta and CTFgamma generation | Q40506128 | ||
| The C-terminus of the beta protein is critical in amyloidogenesis | Q40779575 | ||
| L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity | Q40865987 | ||
| Coumarin-based inhibitors of HIV integrase | Q42551512 | ||
| A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 | ||
| Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines | Q44033487 | ||
| Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors | Q45095870 | ||
| A new dicoumarin and anticoagulant activity from Viola yedoensis Makino | Q46078450 | ||
| Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease | Q46243973 | ||
| Abeta40 inhibits amyloid deposition in vivo. | Q48305645 | ||
| Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. | Q48592298 | ||
| Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. | Q53341822 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | allosteric inhibitor | Q70361704 |
| P304 | page(s) | 20228-20233 | |
| P577 | publication date | 2009-11-11 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Modulation of gamma-secretase specificity using small molecule allosteric inhibitors | |
| P478 | volume | 106 |
| Q36875846 | A novel high throughput 1536-well Notch1 γ -secretase AlphaLISA assay |
| Q34410897 | Activation and intrinsic γ-secretase activity of presenilin 1 |
| Q47270654 | Allosteric Modulation of Intact γ-Secretase Structural Dynamics |
| Q33601580 | Allosteric regulation of protease activity by small molecules. |
| Q28484985 | Allosteric regulation of rhomboid intramembrane proteolysis |
| Q34543713 | Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease |
| Q42426620 | BMS-708,163 targets presenilin and lacks notch-sparing activity |
| Q39306835 | Cell "vision": complementary factor of protein corona in nanotoxicology. |
| Q33813065 | Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats |
| Q33892554 | Characterization of an atypical gamma-secretase complex from hematopoietic origin |
| Q42578574 | Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein |
| Q38101383 | Development and mechanism of γ-secretase modulators for Alzheimer's disease |
| Q40396092 | Development of CBAP-BPyne, a probe for γ-secretase and presenilinase |
| Q39715922 | Development of Sulfonamide Photoaffinity Inhibitors for Probing Cellular γ-Secretase |
| Q41856924 | Development of clickable active site-directed photoaffinity probes for γ-secretase |
| Q34186656 | Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production |
| Q36006799 | Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase |
| Q55266735 | Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. |
| Q35852564 | Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics |
| Q37999084 | Identifying and characterizing promiscuous targets: implications for virtual screening. |
| Q42031496 | In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors |
| Q41164580 | Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate |
| Q38790377 | Intramembrane proteases as drug targets |
| Q34446281 | Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia |
| Q33687945 | Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease |
| Q35136674 | Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. |
| Q40109092 | Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. |
| Q38086743 | Protein fibrillation and nanoparticle interactions: opportunities and challenges |
| Q41781506 | Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation |
| Q47273218 | Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype |
| Q51093204 | Structural and Chemical Biology of Presenilin Complexes. |
| Q41894180 | Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology |
| Q82774835 | Substrate check of gamma-secretase |
| Q34696540 | Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site |
| Q36028390 | Substrate recruitment of γ-secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping. |
| Q42182917 | Targeting cancer stem cells: a new therapy to cure cancer patients. |
| Q28833244 | Targeting the γ-/β-secretase interaction reduces β-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis |
| Q35029189 | The dynamic conformational landscape of gamma-secretase. |
| Q98906938 | The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease |
| Q51047535 | Toward a general predictive QSAR model for gamma-secretase inhibitors. |
| Q92699415 | Toward the Characterization of DAPT Interactions with γ-Secretase |
| Q53262525 | What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. |
| Q33704474 | γ-Secretase Inhibitors and Modulators Induce Distinct Conformational Changes in the Active Sites of γ-Secretase and Signal Peptide Peptidase |
| Q91581374 | γ-Secretase and its modulators: Twenty years and beyond |